IMMX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Immix Biopharma Inc

NASDAQ | IMMX

4.25

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$142.71M

Market Cap

-

P/E Ratio

-0.77

EPS

$4.60

52 Week High

$1.34

52 Week Low

HEALTHCARE

Sector

IMMX Chart

Recent Chart
Price Action

IMMX Technicals

Tags:

IMMX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$115K
Total Revenue $0
Cost Of Revenue $115K
Costof Goods And Services Sold $115K
Operating Income -$23M
Selling General And Administrative $11M
Research And Development $11M
Operating Expenses $23M
Investment Income Net -
Net Interest Income $1M
Interest Income $1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $115K
Income Before Tax -$22M
Income Tax Expense $41K
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$23M
Ebitda -$23M
Net Income -$22M

Revenue & Profitability

Earnings Performance

IMMX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $23M
Total Current Assets $20M
Cash And Cash Equivalents At Carrying Value $18M
Cash And Short Term Investments $18M
Inventory -
Current Net Receivables $2M
Total Non Current Assets $2.8M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $542K
Other Non Current Assets -
Total Liabilities $9.7M
Total Current Liabilities $8.7M
Current Accounts Payable $5.4M
Deferred Revenue -
Current Debt -
Short Term Debt $65K
Total Non Current Liabilities $1M
Capital Lease Obligations $1.1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.1M
Other Current Liabilities $3.2M
Other Non Current Liabilities -
Total Shareholder Equity $13M
Treasury Stock -
Retained Earnings -$75M
Common Stock $2.8K
Common Stock Shares Outstanding $28M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$15M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $115K
Capital Expenditures $1.2M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$1.2M
Cashflow From Financing $16M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$22M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$115K
Total Revenue $0
Cost Of Revenue $115K
Costof Goods And Services Sold $115K
Operating Income -$23M
Selling General And Administrative $11M
Research And Development $11M
Operating Expenses $23M
Investment Income Net -
Net Interest Income $1M
Interest Income $1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $115K
Income Before Tax -$22M
Income Tax Expense $41K
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$23M
Ebitda -$23M
Net Income -$22M

IMMX News

IMMX Profile

Immix Biopharma Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, California, focused on developing innovative tissue-specific therapies for oncology and inflammatory diseases. The company boasts a robust pipeline of drug candidates designed to address significant unmet medical needs in the U.S. and Australia. With a strong commitment to advanced research and strategic partnerships, Immix is emerging as a pivotal player in the biopharmaceutical sector, with the potential to deliver transformative therapies that could significantly alter current treatment paradigms.

LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
NWTN
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
NWTN
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.